{"altmetric_id":941160,"counts":{"readers":{"mendeley":19,"citeulike":0,"connotea":0},"policy":{"unique_users_count":1,"unique_users":["nice"],"posts_count":1},"total":{"posts_count":5},"twitter":{"unique_users_count":4,"unique_users":["oncoblogger","mlazqui","MPAlonso","Tueressalud"],"posts_count":4}},"selected_quotes":["Results from phase III trial comparing gefitinib with chemo for chemo-naive NSCLC with EGFR gene mutations","Updated OS results from NEJ002 Gefinitib vs CBDCA-Tx","Updated overall survival results from a randomized phase III trial (NEJ002)."],"citation":{"abstract":"NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA\/PTX on progression-free survival (PFS). Subsequent analysis was carried out mainly regarding overall survival (OS).","abstract_source":"pubmed","altmetric_jid":"4f6fa4e83cf058f610002280","authors":["T. Nukiwa","Inoue, A.","Kobayashi, K.","Maemondo, M.","Sugawara, S.","Oizumi, S.","Isobe, H.","Gemma, A.","Harada, M.","Yoshizawa, H.","Kinoshita, I.","Fujita, Y.","Okinaga, S.","Hirano, H.","Yoshimori, K.","Harada, T.","Saijo, Y.","Hagiwara, K.","Morita, S.","Nukiwa, T."],"doi":"10.1093\/annonc\/mds214","endpage":"59","first_seen_on":"2012-09-12T06:20:01+00:00","issns":["1569-8041","0923-7534"],"issue":"1","journal":"Annals of Oncology","last_mentioned_on":1466726400,"links":["http:\/\/annonc.oxfordjournals.org\/content\/early\/2012\/09\/10\/annonc.mds214.short?rss=1","http:\/\/dx.doi.org\/10.1093\/annonc\/mds214"],"pdf_url":"http:\/\/annonc.oxfordjournals.org\/content\/early\/2012\/09\/10\/annonc.mds214.full.pdf","pmid":"22967997","pubdate":"2012-01-01T00:00:00+00:00","publisher":"Oxford University Press","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"54","subjects":["neoplasms"],"title":"Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin\u2013paclitaxel for chemo-na\u00efve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)","type":"article","uri":"https:\/\/academic.oup.com\/annonc\/article-lookup\/doi\/10.1093\/annonc\/mds214","volume":"24","mendeley_url":"http:\/\/www.mendeley.com\/research\/updated-overall-survival-results-randomized-phase-iii-trial-comparing-gefitinib-carboplatinpaclitaxe-1"},"altmetric_score":{"score":5.5,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":5.5},"context_for_score":{"all":{"total_number_of_other_articles":7936934,"mean":6.7106933012983,"rank":1382311,"this_scored_higher_than_pct":82,"this_scored_higher_than":6547922,"rank_type":"exact","sample_size":7936934,"percentile":82},"similar_age_3m":{"total_number_of_other_articles":99661,"mean":5.7944368854104,"rank":16644,"this_scored_higher_than_pct":83,"this_scored_higher_than":82925,"rank_type":"exact","sample_size":99661,"percentile":83},"this_journal":{"total_number_of_other_articles":3502,"mean":9.1596378177664,"rank":946,"this_scored_higher_than_pct":72,"this_scored_higher_than":2550,"rank_type":"exact","sample_size":3502,"percentile":72},"similar_age_this_journal_3m":{"total_number_of_other_articles":53,"mean":6.8978461538462,"rank":10,"this_scored_higher_than_pct":81,"this_scored_higher_than":43,"rank_type":"exact","sample_size":53,"percentile":81}}},"demographics":{"poster_types":{"member_of_the_public":2,"practitioner":2},"users":{"twitter":{"cohorts":{"Practitioners (doctors, other healthcare professionals)":2,"Members of the public":2}},"mendeley":{"by_status":{"Researcher":3,"Student  > Doctoral Student":2,"Student  > Ph. D. Student":1,"Student  > Master":4,"Other":6,"Student  > Bachelor":3},"by_discipline":{"Medicine and Dentistry":11,"Agricultural and Biological Sciences":2,"Nursing and Health Professions":3,"Biochemistry, Genetics and Molecular Biology":1,"Pharmacology, Toxicology and Pharmaceutical Science":2}}},"geo":{"twitter":{"IT":1,"ES":2},"mendeley":{"JP":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/oncoblogger\/statuses\/250483976286908416","license":"public","citation_ids":[941160],"posted_on":"2012-09-25T06:36:48+00:00","author":{"name":"Oncoblogger","url":"https:\/\/paper.li\/oncoblogger\/1394190713","image":"https:\/\/pbs.twimg.com\/profile_images\/2124848055\/image_normal.jpg","description":"Medical Oncologist. Independent, not sponsored tweeting about clinical research in medical oncology, supportive care and cancer health policy.","id_on_source":"oncoblogger","tweeter_id":"33449751","geo":{"lt":41.89474,"ln":12.4839,"country":"IT"},"followers":601},"tweet_id":"250483976286908416"},{"url":"http:\/\/twitter.com\/mlazqui\/statuses\/245768538772631552","license":"public","citation_ids":[941160],"posted_on":"2012-09-12T06:19:20+00:00","author":{"name":"Mart\u00edn L\u00e1zaro","url":"http:\/\/www.novedadesenoncologia.blogspot.com","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000653691864\/11d6fb0c77217bfce2c907aa9b0f2ee5_normal.jpeg","description":"Medical oncologist. Lung and genitourinary cancer.","id_on_source":"mlazqui","tweeter_id":"196132848","geo":{"lt":42.23282,"ln":-8.72264,"country":"ES"},"followers":1703},"tweet_id":"245768538772631552"},{"url":"http:\/\/twitter.com\/MPAlonso\/statuses\/245774654889922560","license":"public","rt":["mlazqui"],"citation_ids":[941160],"posted_on":"2012-09-12T06:43:38+00:00","author":{"name":"Manuel P\u00e9rez-Alonso","url":"http:\/\/www.linkedin.com\/in\/manuelperezalonso","image":"https:\/\/pbs.twimg.com\/profile_images\/900317898232692737\/7VvBnLQU_normal.jpg","description":"Profesor universitario, investigador y emprendedor en Biomedicina, Gen\u00e9tica M\u00e9dica y Gen\u00f3mica | Aqu\u00ed s\u00f3lo mis opiniones","id_on_source":"MPAlonso","tweeter_id":"60956542","geo":{"lt":39.5,"ln":-0.75,"country":"ES"},"followers":17720},"tweet_id":"245774654889922560"},{"url":"http:\/\/twitter.com\/Tueressalud\/statuses\/245768748429103105","license":"public","citation_ids":[941160],"posted_on":"2012-09-12T06:20:10+00:00","author":{"name":"Tu eres salud","url":"http:\/\/www.tueressalud.com","image":"http:\/\/a0.twimg.com\/profile_images\/2984468611\/91d5ccac01a320fcff8a537c19c3082e_normal.jpeg","description":"Cada semana un profesional sanitario twittear\u00e1 desde @tueressalud para acercarnos su d\u00eda a d\u00eda laboral. Esta semana contamos con @estigamboa","id_on_source":"Tueressalud","tweeter_id":"614454116","followers":611},"tweet_id":"245768748429103105"}],"policy":[{"title":"Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer: Committee papers","url":"https:\/\/www.nice.org.uk\/guidance\/TA416\/documents\/committee-papers","license":"public","citation_ids":[1086128,15785709,2030373,15785713,15785716,15785719,15785721,3928876,4731302,1305810,583130,4862754,15785727,4450401,941160,4251285,4238713,15785758,527961,624473,997337,1288949,4013900,14070617,2043712,1597955,3056376,2826264,6337257,9707399,15785816,1181996,210406,15785823,2095942,515281,15022944,15785851,848867,3961042,2368120,3395166,15785862,15785868,15785872,1428802,15785873,15785878,15785883,5742416,1823456,5810048,15785889,1837659,148513,1094414,2199730,574515,541606,3314726,15785902,13831913,15785914,4564705,2397989],"posted_on":"2016-06-24T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/ta416\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-3e1779e57ba3b91edceee210cdc322c947d35508602d9a5c962b985dee680466.jpg"}}]}}